OP-1250-003
58 evidence topics · 16 sources
Objective
Original objective for the ribociclib and alpelisib groups
Location and study date
Registry dates and planned enrollment
| Item | Value |
|---|---|
| Study start (actual) | “2022-08-31” |
| Primary completion (estimated) | “2027-12-31” |
| Study completion (estimated) | “2028-01-31” |
| Enrollment (estimated) | “190” |
Ribociclib group: most recent data cutoff and presentation
Atirmociclib group initiation and enrollment
Study design
Dose-escalation method
Eligibility criteria
Ribociclib group: key eligibility criteria
Prior therapy limits by treatment group in the current registry record
Alpelisib group and central nervous system criteria
Treatment
Alpelisib, everolimus, and atirmociclib group regimens
Study outcomes
Rationale for using dose-limiting toxicities as the primary endpoint
Ribociclib group: primary and secondary endpoints by study part
Dose-limiting toxicity observation period in the ribociclib group
Statistical analysis description
Number of participants (Planned and analyzed)
Planned ribociclib group size after the 2023 amendment
Ribociclib group: enrolled and analyzed participants, July 2025 data cutoff
Ribociclib group: participants by cohort, July 2025 data cutoff
| Cohort | Participants |
|---|---|
| Dose escalation, palazestrant 30 mg | “30 mg (n=3)” |
| Dose escalation, palazestrant 60 mg | “60 mg (n=3)” |
| Dose escalation, palazestrant 120 mg | “120 mg (n=3)” |
| Dose expansion, palazestrant 90 mg | “90 mg (n=16)” |
| Dose expansion, palazestrant 120 mg | “120 mg (n=53)” |
Ribociclib group: March 2024 interim analysis population
Ribociclib group: September 2024 interim analysis population
Description of analysis sets
Follow-up calculation and pharmacokinetic sampling
Results
Participant disposition
Ribociclib group: treatment status, July 2025 data cutoff
Ribociclib group: discontinuations due to adverse events
Baseline characteristics
Ribociclib group: baseline demographics and disease characteristics, July 2025 data cutoff
| Characteristic | Palazestrant 90 mg (n=16) | Palazestrant 120 mg (n=56) | Total (N=72) |
|---|---|---|---|
| Median age, years (range) | “60 (25-76)” | “61 (28-85)” | “61 (25-85)” |
| Female sex, n (%) | “16 (100%)” | “56 (100%)” | “72 (100%)” |
| Premenopausal, n (%) | “4 (25%)” | “8 (14%)” | “12 (17%)” |
| ECOG performance status 0, n (%) | “10 (63%)” | “34 (61%)” | “44 (61%)” |
| ECOG performance status 1, n (%) | “6 (38%)” | “22 (39%)” | “28 (39%)” |
| Measurable disease at baseline, n (%) | “12 (75%)” | “37 (66%)” | “49 (68%)” |
| Visceral disease, n (%) | “6 (38%)” | “33 (59%)” | “39 (54%)” |
| No prior line of therapy in the advanced setting, n (%) | “10 (63%)” | “14 (25%)” | “24 (33%)” |
| One prior line of therapy in the advanced setting, n (%) | “5 (31%)” | “26 (46%)” | “31 (43%)” |
| Two prior lines of therapy in the advanced setting, n (%) | “1 (6.3%)” | “12 (21%)” | “13 (18%)” |
| Three prior lines of therapy in the advanced setting, n (%) | “0” | “4 (7%)” | “4 (6%)” |
| Prior CDK4/6 inhibitor in the advanced setting, n (%) | “5 (31%)” | “40 (71%)” | “45 (63%)” |
| Prior aromatase inhibitor in the advanced setting, n (%) | “5 (31%)” | “27 (48%)” | “32 (44%)” |
| Prior fulvestrant in the advanced setting, n (%) | “1 (6%)” | “22 (39%)” | “23 (32%)” |
| Prior chemotherapy in the advanced setting, n (%) | “1 (6.3%)” | “10 (18%)” | “11 (15%)” |
| ESR1 mutation at baseline | “1/15 (7%)” | “14/54 (26%)” | “15/69 (22%)” |
Ribociclib group: prior CDK4/6 inhibitor exposure and ESR1 mutation status
Efficacy results
Ribociclib group: progression-free survival in the 120 mg cohort, including participants with prior CDK4/6 inhibitor treatment
Ribociclib group: maturity of progression-free survival in the 120 mg cohort
Ribociclib group: progression-free survival in the 90 mg cohort
Ribociclib group: objective response rate, July 2025 data cutoff
| Population | Objective response rate (n/n) |
|---|---|
| 90 mg cohort (n=12) | “42% (5/12)” |
| 120 mg cohort (n=32) | “31% (10/32)” |
| Prior CDK4/6i, 120 mg cohort (n=23) | “26% (6/23)” |
| All (n=44) | “34% (15/44)” |
Ribociclib group: responses after prior CDK4/6 inhibitor treatment
Ribociclib group: 6-month progression-free survival and clinical benefit rate, September 2024 data cutoff
Ribociclib group: clinical benefit rate after prior CDK4/6 inhibitor treatment, November 2024 data cutoff
Ribociclib group: pharmacokinetic interaction results
Ribociclib group: steady-state ribociclib 600 mg exposure, October 2023 data cutoff
| Parameter | Ribociclib single agent | Ribociclib in combination with palazestrant |
|---|---|---|
| AUC0-24 ([h*ng/mL]/mg), GeoMean (GeoCV); N | “23,800 (66%); 54” | “25,400 (78%); 8” |
| Cmax (ng/mL/mg), GeoMean (GeoCV); N | “1,820 (62%); 57” | “1,860 (66%); 8” |
| Tmax (h), Median (min–max); N | “2.4 (0.68–7.8); 57” | “4.0 (1.0–6.0); 8” |
Ribociclib group: CYP3A4 interaction mechanism
Everolimus and atirmociclib groups: first data scheduled for December 2026
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Ribociclib group: dose-limiting toxicities and overall severity
Ribociclib group: related treatment-emergent adverse events in at least 25% of participants, n (%)
| Event | 120 mg (n=56), all grades | 120 mg, grade 3 | 120 mg, grade 4 | 90 mg (n=16), all grades | 90 mg, grade 3 | 90 mg, grade 4 |
|---|---|---|---|---|---|---|
| Neutropenia (combined term) | “47 (84%)” | “28 (50%)” | “5 (9%)” | “13 (81%)” | “9 (56%)” | “2 (16%)” |
| Nausea | “41 (73%)” | “2 (4%)” | “0” | “11 (69%)” | “1 (6%)” | “0” |
| Fatigue | “30 (54%)” | “3 (5%)” | “0” | “9 (50%)” | “0” | “0” |
| White blood cell decrease | “24 (43%)” | “9 (16%)” | “1 (2%)” | “6 (38%)” | “4 (25%)” | “0” |
| Diarrhea | “24 (43%)” | “2 (4%)” | “0” | “4 (25%)” | “0” | “0” |
| Anemia | “22 (39%)” | “2 (4%)” | “0” | “5 (31%)” | “0” | “0” |
| Vomiting | “21 (38%)” | “1 (2%)” | “0” | “4 (25%)” | “0” | “0” |
| Electrocardiogram QT prolonged | “16 (29%)” | “4 (5%)” | “0” | “4 (25%)” | “1 (6%)” | “0” |
| Lymphocyte decrease | “16 (29%)” | “3 (5%)” | “1 (2%)” | “3 (19%)” | “0” | “0” |
| AST increased | “15 (27%)” | “2 (4%)” | “0” | “3 (19%)” | “0” | “0” |
| Constipation | “15 (27%)” | “0” | “0” | “3 (19%)” | “0” | “0” |
Ribociclib group: dose reductions and grade 5 events
Ribociclib group: reasons for ribociclib dose reduction, March 2024 data cutoff
Ribociclib group: QTcF in the dose-escalation analysis
Study limitations
Summary
OP-1250-003 is an open-label phase 1b, 2-part study in 4 treatment groups, and the 2025 presentation cautions that its comparison aggregates results across independent studies and carries the risks inherent in cross-trial comparisons. The ribociclib group population differs from this indication: 24 of 72 participants (33%) had no prior line of therapy in the advanced setting, and 45 (63%) had received a prior CDK4/6 inhibitor. Cohorts include 16 participants at palazestrant 90 mg and 56 at 120 mg, and response rates are based on 12 and 32 response-evaluable participants, respectively. The presentation describes efficacy as “maturing”: 30 of 72 participants (42%) remained on treatment at the July 8, 2025 cutoff, and median PFS in the 90 mg cohort was not reached at a median follow-up of 10.8 months. Responses were assessed by the investigator, and the analysis presented 72 of 78 enrolled participants. Interim results were reported at successive cutoffs (March 13, 2024; September 25, 2024; and July 8, 2025) with different analysis populations.